GTS Securities’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-104,800
Closed -$178K 3228
2024
Q3
$178K Sell
104,800
-22,000
-17% -$36.1K ﹤0.01% 3687
2024
Q2
$174K Buy
126,800
+81,700
+181% +$165K ﹤0.01% 3494
2024
Q1
$169K Sell
45,100
-58,200
-56% -$341K ﹤0.01% 3397
2023
Q4
$1.01M Sell
103,300
-4,200
-4% -$34.3K ﹤0.01% 2157
2023
Q3
$898K Buy
+107,500
New +$1.23M ﹤0.01% 2100

Other funds holding PACB

GTS Securities's PACB Position: Q1 2026 in Review

GTS Securities opened a new position in Pacific Biosciences (PACB) in Q1 2026: 17,133 shares worth $22.6K. The stake represents ﹤0.01% of the portfolio and ranks #1456 among its holdings. This is a return to the name: GTS Securities previously reported a position in PACB as recently as Q3 2025.

GTS Securities first reported a position in PACB in Q2 2023 and has held it in 9 quarters since. The position peaked at $3.11M in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • GTS Securities held 17,133 shares of Pacific Biosciences worth $22.6K as of Q1 2026.
  • Pacific Biosciences was a new GTS Securities position in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1456 holding.
  • GTS Securities first reported a position in Pacific Biosciences in Q2 2023 and has held it in 9 quarters since.
  • GTS Securities's Pacific Biosciences position peaked at $3.11M in Q4 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.